The first stop for professional medicines advice

Size: px
Start display at page:

Download "The first stop for professional medicines advice"

Transcription

1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1

2 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues Licensing(L)/NICE Approval(N) Dual Therapy Triple Therapy Renal Impairment Drug Name Available Preparations Route Dosing Frequency Cost per year (as per BNF March 2016) *1 Monotherapy Metformin Sulphonylurea Pioglitazone Basal Insulin L L L L L NICE L NICE L L L L L L Metformin & Sulphonylurea Sulphonylurea & Pioglitazone Metformin & Pioglitazone Basal Insulin + Metformin Basal Insulin + Sulphonylurea Basal Insulin + Basal Insulin + metformin + NICE Evidence Base <30ml/min or End Stage Renal Disease 30-50ml/min 50-80ml/min Liver Impairment Drug-specific cautions Impact on weight loss Hypoglycaemic events Exenatide Liraglutide Lixisenatide Dulaglutide Albiglutide Standard Release Byetta Modified Release Bydureon Victoza Insulin degludec Xultophy Lyxumia Trulicity Eperzan SUBCUTANEOUS Twice Daily In adults type 2 diabetes, only offer a GLP- Once 1 analogue in Weekly combination insulin specialist care Once advice and Daily * * ongoing support * * * * * * * Once Daily from a consultantled Range from to multidisciplinary team 1, * * * * * * * * * * * * Once Daily * * * * * * * * * * * Once Weekly * * * * * * * * * Not addressed Once Weekly * * * * * * * * * * * Not addressed 2nd intensification therapy ** **If triple therapy metformin and 2 other oral drugs is not effective, not tolerated or contraindicated, combination therapy metformin, sulfonylurea + a GLP-1 analogue can be considered if HbA1C >7.5%, BMI 35kg/m 2 OR BMI <35kg/m 2 and insulin therapy would have significant occupational implications/weight loss would benefit other significant obesity related comorbidities. See Overleaf and Appendix 1 Not recommended Dose escalation from 5 to 10mcg should proceed conservatively Not recommended - limited clinical experience No dose adjustment required No dose adjustment required No dose adjustment required No dose adjustment required No dose adjustment required Use intensified glucose monitoring and subsequent dose adjustment on an individual level No dose adjustment required No dose adjustment required No dose adjustment required in mild to moderate impairment. Use is not recommended in severe impairment Not recommended due to limited evidence base No dose adjustment required No dose adjustment required No dose adjustment required Nil specific to exenatide Thyroid adverse events, including increased blood calcitonin, goitre and thyroid neoplasm have been reported in clinical trials in particular in patients preexisting thyroid disease and liraglutide should therefore be used caution. Nil specific to lixisenatide Nil specific to dulaglutide Nil specific to albiglutide According to NICE's meta-analysis, in general combinations of 3 non-insulin drugs were generally associated weight gain except for combinations GLP-1 agonists (evidence base for exenatide/liraglutide+ metformin+sulphoylur ea considered), which showed a trend for weight loss when compared to metformin+nph insulin. According to NICE's meta-analysis, three noninsulin based drug combinations (including 2nd intensification GLP-1 analogues) were generally associated less hypoglycaemic events compared to the metformin-nph insulin combination. Not addressed by NICE guidance Key Licensed for use, no cautions and no dose adjustments required Byetta *1 Calculation of Annual Cost Based on a dose of 10mcg exenatide twice daily Use caution as risk of hypoglycaemia is increased, therefore manufacturers advise to consider dose reduction of /basal insulin when GLP-1 analogue added to reduce this risk Mentioned in section 4.2 of SPC although no data specifically supporting these combinations. Not Licensed for use Not addressed by NICE License states "in combination other glucose-lowering medicinal products including basal insulin, when these, together diet and exercise, do not provide adequate glycaemic control." These combinations are those for which supporting data are available in the product information, although the decision to prescribe is left to * the discretion of the clinician. Trulicity License states "in combination other glucose-lowering medicinal products including basal insulin, when these, together diet and exercise, do not provide adequate glycaemic control." These combinations are those for which supporting data are not available in the product information, although the decision to prescribe is * left to the discretion of the clinician. Eperzan Bydureon Victoza Xultophy Lyxumia Based on dose of 2mg exenatide once a week Based on liraglutide dose of 1.2mg once a day Annual cost ranges from for a daily dose of 10 dose-steps (10 units insulin degludec and 0.36 mg liraglutide) to for a daily dose of 50 dose-steps (50 units insulin degludec and 1.8 mg liraglutide). Based on lixisenatide dose of 20mcg once daily Based on dulaglutide dose of either 0.75mg/week (monotherapy) or 1.5mg/week (combination therapy) Based on albiglutide dose of either 30mg (starting dose) or 50mg once a week (maximum dose) 2

3 Brief summary of evidence base for GLP-1 Analogues in diabetes Drug Preparation Brief Summary of pivotal studies Exenatide Standard Release Byetta Modified Release Bydureon The safety and efficacy of standard release exenatide was investigated in eight key studies (six placebo-controlled, two active-comparator controlled) which included 3,067 patients type 2 diabetes 1-5. Six randomised comparator-controlled studies were conducted to evaluate the effects of Bydureon on glycaemic control a range of background therapies. A total of 3,225 patients were included in the studies Six phase III trials (five double-blind and one open label) were conducted to evaluate the effects of liraglutide on glycaemic control a range of background therapies. A total of 3,968 patients were included in these studies Liraglutide Lixisenatide Dulaglutide Albiglutide Victoza Insulin degludec Xultophy Lyxumia Trulicity Eperzan Additional trials were conducted liraglutide that included 1,901 patients in four unblinded randomised controlled trials 12. Of these studies, one key phase 3b study which reports the use of liraglutide as add on therapy to basal insulin in 177 patients has been included 18. A recent study (published June 2016) comparing once daily liraglutide vs. lixisenatide as add-on therapy to metformin in 404 patients was also included 19. The safety and efficacy of Xultophy has been established based on three published randomised controlled phase III studies including 2,630 patients Type 2 diabetes on a range of background therapies One unpublished study including 435 patients on background therapy a ± metformin was also included as it has been highlighted in the summary of product characteristics for Xultophy 20. The clinical efficacy and safety of lixisenatide were evaluated in nine randomised double-blind, placebo-controlled clinical studies including 4,509 patients type 2 diabetes Efficacy of lixisenatide was also assessed in one pivotal randomised, open-label, active-controlled study (versus exenatide) (in total 634 patients randomised to either lixisenatide or exenatide) 33. A recent study (published June 2016) comparing once daily liraglutide vs. lixisenatide as add-on therapy to metformin in 404 patients was also included 19. The safety and efficacy of dulaglutide was evaluated in six randomised, controlled, phase III trials involving 5,171 patients type 2 diabetes All six studies compared dulaglutide to an active comparator, and one of the studies was both active and placebo controlled. The safety and efficacy of albiglutide was evaluated in eight active and placebo-controlled phase III clinical trials including a total of 4,840 patients type 2 diabetes. Studies evaluated the use of albiglutide 30 mg and 50 mg once weekly, allowing for optional titration of albiglutide from 30 mg to 50 mg once weekly in 5 of the 8 studies 40. 3

4 Appendix 1: Summary of primary endpoint data for pivotal studies of GLP-1 Analogues in diabetes Drug Preparation License Evidence Base Exenatide Byetta Standard Release Summary The safety and efficacy of standard release exenatide was investigated in eight key studies (six placebocontrolled, two active-comparator controlled) which included 3,067 patients type 2 diabetes 1-5. metformin Triple-blind placebo-controlled study (n=336) found in patients treated on background therapy metformin, exenatide at doses of 5mcg and 10mcg twice daily was superior to placebo in reduction of HbA1c from baseline at 30 weeks (-0.40%, -0.78%, and +0.08%, respectively [p<0.002]) 1. Triple-blind placebo-controlled study (n=377) found in patients treated on background therapy s, exenatide at doses of 5 mcg and 10 mcg twice daily was superior to placebo in the reduction of HbA1c from baseline at 30 weeks (-0.46%, -0.86%, and +0.12%, respectively [p<0.001]) 2. metformin + metformin + basal insulin basal insulin + metformin basal insulin + basal insulin + metformin + Double-blind placebo-controlled study (n=733) found in patients treated on background therapy metformin+, exenatide at doses of 5mcg and 10mcg twice daily was superior to placebo in the reduction of HbA1c from baseline at 30 weeks (-0.6%, -0.8%, and +0.12%, respectively [p<0.0001]) 3. Two placebo-controlled studies (one of 16-week duration, and one of 26-week duration 233 and 165 participants, respectively) adding exenatide to existing thiazolidinedione treatment ± metformin. Of the exenatide patients in both studies (n=232), 12% were treated a thiazolidenedione and exenatide and 82% were treated thiazolidinedione treatment, metformin and exenatide. Both studies showed statistically significant reductions in HbA1c from baseline compared to placebo (-0.7% vs. +0.1% in the 16-week study and -0.8% vs. -0.1% in the 26-week study for exenatide vs. placebo, respectively) 4. Three studies measuring the efficacy of exenatide in combination basal insulin were conducted: The first was a placebo-controlled study (n=259) in patients on insulin glargine (alone [15%], metformin [70%], [3%] or metformin+ [12%]). At the end of a 30-week period, exenatide demonstrated a statistically significant reduction in the HbA1c compared to placebo (-1.74% vs %, p<0.001) 5. The second was a 24-week study (n=337), in which either insulin lispro protamine suspension or insulin glargine were added to existing therapy of Byetta and metformin, metformin and or metformin and (exact patient characteristics not available) (1.2% vs. 1.4%, respectively) 4. The third was a 30-week open-label, active comparator-controlled non-inferiority study (n=627) in patients on a background of optimised basal insulin glargine and metformin. Non-inferiority in reduction of HbA1c of Byetta to titrated insulin lispro was demonstrated (-1.1% reduction in HbA1c from baseline [at 30 weeks] for both insulin glargine and metformin) 4. 4

5 Drug Preparation License Evidence Base Exenatide Bydureon Modified Release Summary Six randomised comparator-controlled phase III studies were conducted to evaluate the effects of Bydureon on glycaemic control a range of background therapies. A total of 3,225 patients were included in the studies In addition to the studies described below, a 26-week RCT (n=820) in drug-naive patients found that Bydureon as monotherapy was non-inferior to metformin (2000mg/day) but not to (45mg/day) and was superior to sitagliptin (100mg/day) in change in HbA1c from baseline at 26 weeks (-1.53%, -1.48%, -1.63%, and -1.15%, respectively). This study was designed to test superiority if non-inferioity was established 6. metformin metformin + Metformin alone: One 26-week randomised double blind superiority study (n=491) found for patients on background therapy metformin, Bydureon was superior to both sitagliptin and in reduction of HbA1c from baseline at 26 weeks (- 1.5%, -0.9%, and -1.2%, respectively [p< for exenatide vs. sitagliptin and p= for exenatide vs. ]) 7. Various background therapies: One 25-week open-label randomised superiority study (n=456) found for patients on background treatment either metformin only (70%) and metformin+ (30%), that change in HbA1c from baseline at 26 weeks was greater in patients taking Bydureon compared to those taking insulin glargine (-1.5% vs. -1.3%, respectively[p=0.017]) 8. A 30-week open-label randomised non-inferiority study (n=295) in patients naïve to drug therapy (15%), or on pharmacological treatment (metformin (36%), (5%) or thiazolidenedione (3%), metformin+ (28%) or metformin+thiazolidenedione (9%)) found, at 30 weeks Bydureon was non-inferior to Byetta in reduction of HbA1c from baseline (-1.9% vs. -1.5% respectively [p=0.0023]). Baseline characteristics for previous therapy only documented for 284 patients (96%) 9. A 24-week open-label comparator-controlled study (n=252) in patients on a variety of background medications (19% drug naive, 47% taking one oral antidiabetic, and 35% taking multiple oral antidiabetics; 75% of study population were taking metformin, 29% were taking s, and 14% were taking thiazolidenediones) found at 24-weeks Bydureon was superior to Byetta in reduction of HbA1c from baseline (-1.6% vs. -0.9%, p<0.0001). This study was designed the power to detect non-inferiority, but superiority hypotheses were also specified in the protocol and tested for if non-inferiority was achieved 10. A 26-week open-label non-inferiority study (n=911) found that Bydureon did not meet the specified non-inferiority criteria vs. liraglutide (1.8mg daily) for reduction in HbA1c from baseline although both led to improvements in glycaemic control (-1.28% vs %). Patients included in this study were on a range of background therapies; metformin + (60.6%), metformin alone (31.4%), alone (4%), metformin+ (3.7%), metformin++ (0.2%), alone (0.1%) 11. 5

6 Drug Preparation License Evidence Base Liraglutide Victoza Summary Six phase III trials (five double-blind and one open label) were conducted to evaluate the effects of liraglutide on glycaemic control a range of background therapies. A total of 3,968 patients were included in these studies Additional trials were conducted liraglutide that included 1,901 patients in four unblinded randomised controlled trials 12. Of these studies, one key phase 3b study which reports the use of liraglutide as add on therapy to basal insulin in 177 patients has been included 18. A recent study (published June 2016) comparing once daily liraglutide vs. lixisenatide as add-on therapy to metformin in 404 patients was also included 19. Monotherapy Double-blind randomised controlled trial (n=745) found liraglutide monotherapy for 52 weeks resulted in statistically superior reductions in HbA1c vs. glimepiride 8mg/day (-0.84% for 1.2mg liraglutide, -1.14% for 1.8mg liraglutide vs % for glimepiride, metformin metformin + metformin + basal insulin p<0.01 and p<0.0001, respectively) 12. Double blind randomised placebo and active-controlled trial (n=845) found at 26 weeks in patients on background metformin therapy, liraglutide (1.2mg and 1.8mg) were superior to placebo in change in HbA1c from baseline (p<0.0001) and non-inferior to active comparator glimepiride (-0.97%, -1.00%, +0.09%, and -0.98% for liraglutide 1.2mg, liraglutide 1.8mg, placebo, and glimepiride 4mg/day, respectively [p< for both superiority and non-inferiority]) Open-label, randomised, parallel group study (n=404) found at 26 weeks in patients on background metformin therapy, 1.8mg liraglutide reduced HbA1c more than 20µg lixisenatide (difference -0.62%, p<0.0001). Body weight reductions were similar and both treatments were well tolerated, low risk of hypoglycaemia 19. Double blind randomised placebo and active-controlled trial (n=808) found at 26 weeks when added on to glimepiride, liraglutide (1.2mg and 1.8mg) was superior both placebo and rosiglitazone 4mg/day in change in HbA1c from baseline (-1.08%, -1.13%, +0.23%, -0.44% for liraglutide 1.2mg, liraglutide 1.8mg, placebo, and rosiglitazone 4mg/day, respectively [p< for all].) In this study, superiority to placebo was tested first then non-inferiority to rosiglitazone, and then finally superiority of liraglutide to rosglitazone 12,14. Double blind randomised controlled trial (n=576) where liraglutide 1.8mg was added on to metformin 2000mg/day + glimepiride 4mg/day found liraglutide was superior for change in HbA1c to both placebo and active comparator insulin glargine (-1.33%, -0.24%, and -1.09%, [p< vs. placebo and p<0.01 vs. insulin glargine]).this study was designed power to detect both non-inferiority and superiority, first superiority of liraglutide vs. insulin glargine was proven, followed by non-inferiority of liraglutide to insulin glargine, and if proven lead to testing of superiority of liraglutide to insulin glargine 12,15. Open label non-inferiority randomised controlled study (n=464) comparing the efficacy and safety of liraglutide 1.8 mg once daily and exenatide 10 mcg twice daily in patients inadequately controlled on therapy metformin alone (27%), alone (10%) or both (63%), liraglutide was statistically superior to exenatide treatment in reducing HbA1c after 26 weeks (-1.12% vs -0.79%, p<0.0001). The investigators first established non-inferiority and then tested for superiority in this study 12,16. Double blind randomised controlled trial (n=530) found at 26 weeks when added on to metformin 2000mg/day + rosiglitazone 4mg/day, liraglutide 1.2mg and 1.8mg were superior to placebo in the reduction of HbA1c from baseline (-1.48%, -1.48%, and %, respectively [p<0.0001]) 17. In a 104-week clinical trial, 57% of patients type 2 diabetes treated insulin degludec in combination metformin achieved a target HbA1c <7% and the remaining patients continued in a 26-week phase 3b open label trial (n=177) and were randomised to add liraglutide or a single dose of insulin aspart ( the largest meal). In the insulin degludec + liraglutide arm, the insulin dose was reduced by 20% in order to minimize the risk of hypoglycaemia. Addition of liraglutide resulted in a statistically significantly greater reduction of HbA1c (-0.73% for liraglutide vs -0.40% for insulin aspart, p=0.0024) 12,18. 6

7 Drug Preparation License Evidence Base Liraglutide Xultophy Summary The safety and efficacy of Xultophy has been established based on three published randomised controlled phase III insulin degludec studies including 2,630 patients Type 2 diabetes on a range of background therapies. One unpublished study including 435 patients on background therapy a ± metformin was also included as it has been highlighted in the summary of product characteristics for Xultophy In addition to the studies described below, a non-inferiority study (n=557) found that in patients uncontrolled Type 2 diabetes on insulin glargine+metformin, Xultophy was non-inferior to insulin glargine+metformin up-titration of insulin in reduction of HbA1c (-1.81% vs %, respectively [p<0.001 for non-inferiority]) 21. metformin metformin + metformin + Open-label randomised controlled study (n=1660) found that at 26 weeks Xultophy was non-inferior to insulin degludec and superior to liraglutide in reduction of HbA1c from baseline at 26 weeks (change in HbA1c-1.91%, -1.44% and %, respectively [p<0.0001]) in patients on background therapy of metformin ± (17% on both metformin and ) 22. Double-blind randomised controlled study (n=413) found that at 26 weeks, Xultophy was superior to insulin degludec alone in patients on background therapy metformin in reduction of HbA1c (-1.9% vs. -0.9%, respectively [p<0.0001]) 23. One 26-week randomised, placebo-controlled, double-blind, treat-to-target trial (n=435 patients) found that the change in HbA1c from baseline was significantly greater Xultophy compared to placebo (-1.45% vs %, p<0.0001) in patients on background therapy ± metformin. (unpublished data, cited in product information 20 ) 7

8 Drug Preparation License Evidence Base Lixisenatide Lyxumia Summary The clinical efficacy and safety of lixisenatide were evaluated in nine randomised double-blind, placebo-controlled clinical studies including 4,509 patients type 2 diabetes A recent study (published June 2016) comparing once daily liraglutide vs. lixisenatide as add-on therapy to metformin in 404 patients was also included 19. In addition, a 12 week double-blind randomised placebo-controlled study (n=361) was conducted in patients not on glucose lowering therapy. The study found lixisenatide (either 2 step [10mcg for 1 week, 15mcg for week and then 20mcg] or 1 step [10mcg for 2 weeks then 20mcg]) was superior to placebo (either 1 or 2 step) in reduction of HbA1c from baseline (-0.19%, %, and -0.85% for combined placebo, lixisenatide 2 step, and lixisenatide 1 step respectively [p<0.0001]) 33. metformin Randomised double-blind placebo controlled study (n=680) in patients on background therapy metformin which compared lixisenatide vs. placebo (morning or evening) found lixisenatide morning injection significantly reduced mean HbA1c vs. combined placebo at 24-weeks (-0.9% vs -0.4%, p<0.0001) 24. Randomised double-blind placebo-controlled study (n=482) in patients on background therapy metformin randomised to receive either lixisenatide in a one-step dose increase or a two-step dose increase vs. placebo for 24 weeks. Lixisenatide one- /two-step once daily significantly improved HbA1c vs. placebo at week 24 (-0.9%, -0.8%, and -0.4%, respectively [p<0.0001]) 25. Non-inferiority study (n= 634) in patients uncontrolled diabetes on background therapy metformin found that lixisenatide 20mcg one daily was non-inferior to exenatide 10mcg twice daily in HbA1c change from baseline to week 24 (- 0.79% vs %, respectively) 26. A recent study (published June 2016) comparing once daily liraglutide vs. lixisenatide as add-on therapy to metformin in 404 metformin + ± metformin basal insulin + basal insulin + metformin basal insulin + patients have been described above in the liraglutide table 19. Randomised double-blind placebo controlled study (n=859) in patients inadequately controlled on ± metformin (84% patients on +metformin) found lixisenatide provided a significant reduction in HbA1c at week 24 vs. placebo (-0.85% vs -0.10%, p<0.0001) 27. Randomised double-blind placebo-controlled study (n=391) in Asian patients uncontrolled on metformin ± (44.6%) found at week 24 reduction in HbA1c from baseline was significantly greater lixisenatde vs. placebo (-0.83% vs %, p=0.0004) 28. Randomised double-blind placebo-controlled study (n=484) in patients on at a stable dose of 30mg/day±metformin on a stable dose of 1500mg/day (81% of patients included in the study were on both and metformin) found after 24 weeks, lixisenatide once daily significantly improved HbA1c vs. placebo (-0.9% vs %, p<0.0001) 29. Randomised double-blind placebo-controlled study (n=311) found that in Asian patients insufficiently controlled on basal insulin ± (70% on both), lixisenatide was superior in reducing HbA1c at week 24 compared to placebo (-0.77% vs %, respectively [p<0.0001]) 30. Randomised double-blind placebo-controlled study (n=446) in patients HbA1c 7-10% despite oral therapy in whom insulin glargine was added and systematically titrated during a 12 week run-in. Adding lixisenatide after run-in further reduced HbA1c by 0.71% vs. 0.40% placebo (p<0.0001) at 24 weeks. All patients included in the study were on background therapy metformin (stable dose of at least 1500mg/day for at least last 3 months), 12% of participants were also on thiazolidenediones 31. Randomised double-blind placebo-controlled study (n=495) in patients inadequately controlled on basal insulin ± metformin (79% of patients on metformin) found lixisenatide was superior in reduction of HbA1c from baseline at 24 weeks compared to placebo (-0.6% vs. -0.3%) 32. 8

9 Drug Preparation License Evidence Base Dulaglutide Trulicity Summary The safety and efficacy of dulaglutide was evaluated in six randomised, controlled, phase III trials involving 5,171 patients type 2 diabetes. All six studies compared dulaglutide to an active comparator, and one of the studies was both active and placebo controlled Monotherapy Active controlled study (n=807) was designed to detect non-inferiority of dulaglutide 1.5mg versus metformin on HbA1c change from baseline at 26-weeks. If non-inferiority was met, superiority was assessed. The study found monotherapy dulaglutide 1.5 mg and 0.75 mg was superior to metformin ( mg/day) in the reduction of HbA1c at 26 weeks (-0.78%, -0.71%, and -0.56%, respectively [p<0.025]) 34. metformin One 104-week study (n=1098) found in patients taking metformin, treatment dulaglutide 1.5 mg and 0.75 mg resulted in a superior reduction in HbA1c compared to sitagliptin (100mg daily) at 52 weeks (-1.10%, -0.87%, and %, [p<0.025]) 35. An 26-week non-inferiority study (n=599) found in patients taking metformin, treatment dulaglutide 1.5 mg was non-inferior to liraglutide 1.8mg in reducing HbA1c from baseline (-1.42% vs %, p<0.001 for noninferiority) 36. basal insulin ± metformin metformin + metformin + Non-inferiority study (n=884) in which patients discontinued their prestudy insulin regimen and were randomised to dulaglutide once weekly or insulin glargine once daily, both in combination prandial insulin lispro three times daily, or out metformin. The same statistical model was used to assess non-inferiority and superiority of dulaglutide doses versus glargine, a gatekeeping strategy to control family-wise type 1 error rate. At 26 weeks, both 1.5 mg and 0.75mg dulaglutide were superior to insulin glargine in lowering of HbA1c (-1.64%, -1.59%, and %, respectively [p<0.025 for superiority]) 37. Open-label comparator randomised controlled study (n=807) found at 52 weeks dulaglutide 1.5mg was superior to insulin glargine for reduction of HbA1c from baseline in patients taking both metformin+ (1.08% vs %, p<0.025 for superiority). Dulaglutide 0.75 mg was non-inferior to insulin glargine(-0.76% vs %, p< for noninferiority). The study was designed 90% power to show non-inferiority of dulaglutide 1.5mg vs. insulin glargine for change from baseline HbA1c at the 52-week primary endpoint, if non-inferiority was achieved, tree-gatekeeping was used to control the type 1 error rate at while assessing the superiority of dulaglutide 1.5 mg versus glargine and the non-inferiority or superiority of dulaglutide 0.75 mg versus glargine for the change from baseline in HbA1c at 52 weeks 38. In a placebo and active (exenatide twice daily) controlled study (n=976), in combination metformin and, dulaglutide 1.5 mg and 0.75 mg demonstrated superiority for HbA1c reduction in comparison to placebo at 26-weeks (-1.51%, -1.30% and -0.46%, respectively [p<0.001]). The study was powered to assess the non-inferiority of dulaglutide vs. exenatide, but analysis found that both strengths of dulaglutide (1.5mg and 0.75mg) were superior to exenatide 10 mcg for HbA1c reduction (-1.51%, -1.30%, and -0.99%, respectively [p<0.025]) 39. 9

10 Drug Preparation License Evidence Base Albiglutide Eperzan Summary The safety and efficacy of albiglutide was evaluated in eight active and placebo-controlled phase III clinical trials including a total of 4,840 patients type 2 diabetes 40. Studies evaluated the use of albiglutide 30 mg and 50 mg once weekly, allowing for optional titration of albiglutide from 30 mg to 50 mg once weekly in 5 of the 8 studies. In addition to the seven studies described below, the efficacy of albiglutide was also evaluated in a 32-week randomised, open-label, liraglutide-controlled non-inferiority study (n=808) in patients inadquately controlled on monotherapy or combination therapy metformin, a thiazolidenedione, or ). Treatment albiglutide did not meet the pre-specified noninferiority margin (0.3%) against liraglutide for change in HbA1c from baseline at 32 weeks (-0.8% vs. -1.0%, p=0.0846) 40. Monotherapy Study (n=296) in patients inadequately controlled on diet or exercise found treatment albiglutide 30mg and 50mg weekly resulted in statistically significant reductions in HbA1c from baseline at 52 weeks vs. placebo ( -0.70%, -0.9%, and +0.2% respectively [p<0.05 for treatment difference]) 40. metformin Study (n = 999) of patients on background therapy of metformin 1,500 mg daily. Albiglutide 30 mg weekly ( optional uptitration to 50 mg weekly after a minimum of 4 weeks) was compared to sitagliptin 100 mg daily, glimepiride 2 mg daily ( optional titration to 4 mg daily), or placebo. At 104 weeks, albiglutide was statistically superior in reduction in HbA1c from baseline compared to placebo, sitagliptin, or glimepiride (-0.6%, +0.3%, -0.3% and -0.4%, respectively [p<0.05 for treatment difference]) 40. metformin ± Study (n=657) in patients on background therapy of metformin 1,500 mg daily+glimepiride 4 mg daily, albiglutide 30 mg SC weekly ( optional uptitration to 50 mg weekly after a minimum of 4 weeks) was compared to placebo or 30 mg daily ( optional titration to 45 mg/day) found at 52 weeks treatment albiglutide resulted in statistically significant reductions from baseline in HbA1c compared to placebo (-0.6% versus %, p<0.05 for treatment difference). Treatment albiglutide did not meet the pre-specified noninferiority margin (0.3%) against for HbA1c 40. Non-inferiority study of albiglutide vs. insulin-glargine (n=735) in patients on background of metformin 1,500 mg daily ± found at 52 weeks, change in HbA1c was -0.7% and -0.8%, respectively. Albiglutide was noninferior to insulin glargine as the between-treatment difference in HbA1c from baseline at 52 weeks met the prespecified noninferiority margin (0.3%) 40. Study (n=299) in which albiglutide 30 mg weekly was compared to placebo in patients inadequately controlled on 30 mg daily± metformin 1,500 mg daily. At 52 weeks, treatment albiglutide resulted in statistically significant reductions from baseline in HbA1c vs. placebo (-0.8% vs. -0.1% for placebo, p<0.05) 40. insulin glargine Non-inferiority study (n=563) of patients on background therapy insulin glargine compared albiglutide 30 mg once weekly ( up titration to 50 mg if inadequately controlled after Week 8) to prandial insulin lispro. Albiglutide was found to be non-inferior to insulin lispro the between-treatment difference in HbA1c of 0.2% for albiglutide and insulin lispro (-0.8% and -0.6%, respectively) at 26 weeks meeting the pre-specified noninferiority margin (0.4%)

11 * Published Phase 3 studies unless cited as unpublished data cited in summary of product characteristics. References 1. DeFronzo R et al. Effects of Exenatide (Exendin-4) On Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients Type 2 Diabetes. Diabetes Care 2005;28: Buse JB et al. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 weeks in Sulfonylurea-Treated patients With Type 2 Diabetes. Diabetes Care 2004;27: Kendall D et al. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea. Diabetes Care 2005;28: Summary of Product Characteristics: Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen. Last revised: 16th December AstraZeneca UK Limited. Accessed online via: on 29/07/ Buse JB et al. Use of Twice-Daily Exenatide in Basal Insulin Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial. Annals of Internal Medicine 2011;154: Russell-Jones D et al. Efficacy and Safety of Exenatide Once WeeklyVersus Metformin,Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive PatientsWith Type 2 Diabetes (DURATION-4). Diabetes Care 2012;35: Bergenstal RM et al. Efficacy and safety of exenatide once weekly versus sitagliptin or as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376: Diamant M et al. Once weekly exenatide compared insulin glargine titrated to target in patients type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375: Drucker D et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372: Blevins T et al. DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared Exenatide Twice Daily in Patients Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism 2011;96(5): Buse JB et al. Exenatide once weekly versus liraglutide once daily in patients type 2 diabetes (DURATION- 6): a randomised, open-label study. Lancet 2013;381: Summary of Product characteristics: Victoza 6mg/ml solution for injection in pre-filled pen. Last revised: 05/2016. Novo Nordisk Limited. Accessed online via: on 28/07/ Nauck M et al. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care 2009;32: Marre M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a over 26 weeks produces greater improvements in glycaemic and weight control compared adding rosiglitazone or placebo in subjects Type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009;26: Russell-Jones D et al. Liraglutide vs insulin glargine and placebo in combination metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+su): a randomised controlled trial. Diabetologia 2009;52: Buse JB et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multi-national, open-label trial (LEAD-6). Lancet 2009 Jul 4;374(9683): Zinman B et al. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met TZD). Diabetes Care 2009;32: Mathieu C et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes, Obesity and Metabolism 2014;16(7): Nauck M et al. Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-week Randomized Controlled Clinical Trial. Diabetes Care 2016; dc Summary of Product Characteristics: Xultophy 100 units/ml insulin deguladec + 3.6mg/mL liraglutide solution for injeciton in a pre-filled pen. Last revised: 02/2016. Novo Nordisk Limited. Accessed online via: on 29/07/ Lingvay I. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes - The DUAL V Randomized Clinical Trial. JAMA. 2016:315(9): Gough S et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients type 2 diabetes. Lancet 2014;2: Buse JB et al. Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care 2014;37:1 8 11

12 24. Ahrén B et al. Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M). Diabetes Care 2013;36: Bolli GB et al. Efficacy and safety of lixisenatide oncedaily vs.placebo in people Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabetic Medicine 2014;31: Rosenstock J et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 2013;36(10): Rosenstock J et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels out significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea or out metformin (GetGoal-S). Journal of Diabetes and its Complications 2014;28(3): Pan CY et al. Lixisenatide in Asian Patients Type 2 Diabetes (T2DM) Uncontrolled on Metformin ± Sulfonylurea (SU): GetGoal-M Asia. Diabetes/Metabolism Research and Reviews 2014;30(8): Pinget M et al. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on (GetGoal-P). Diabetes, Obesity and Metabolism 2013;15: Seino Y et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients type 2 diabetes insufficiently controlled on basal insulin or out a sulfonylurea (GetGoal-L-Asia). Diabetes Obesity and Metabolism 2012;14(10): Riddle M et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. Diabetes Care 2013;36: Riddle M et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care 2013;36: Fonseca V et al. Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. Diabetes Care 2012;35: Umpierrez G et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014;37(8): Nauck M et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014;37(8): Dungan K M et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet 2014;384: Blonde L et al. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination prandial insulin lispro in patients type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, noninferiority study. Lancet 2015;385: Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015;38(12): Wysham C et al. Efficacy and Safety of Dulaglutide Added onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37(8): Summary of Product Characteristics: Eperzan 30mg powder and solvent for solution for injection. Last revised: 31st March GlaxoSmithKline UK. Accessed online via: on 29/07/2016 Bibliography Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press Electronic Medicines Compendium accessed online via: National Institute for Health and Care Excellence. Diabetes Type 2 diabetes in adults: management NICE guidelines [NG28] Published date: December 2015 UpToDate. Wolters Kluwer. European Medicines Agency Author Suhayla Dhanji Contact details Suhayla Dhanji/David Erskine, London Medicines Information Service: medicinesinformation@gstt.nhs.uk 12

Selecting GLP-1 RA Treatment

Selecting GLP-1 RA Treatment Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Bulletin Glucagon-like peptide 1 (GLP-1) receptor agonist review

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Bulletin Glucagon-like peptide 1 (GLP-1) receptor agonist review BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2017 Review February 2020 Bulletin 245 - Glucagon-like peptide 1 (GLP-1) receptor agonist review JPC Recommendations:- Place in therapy

More information

Achieving and maintaining good glycemic control is an

Achieving and maintaining good glycemic control is an Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,

More information

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited

exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited exenatide 2mg powder and solvent for prolonged-release suspension for injection (Bydureon ) SMC No. (748/11) Eli Lilly and Company Limited 09 December 2011 The Scottish Medicines Consortium (SMC) has completed

More information

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary

GLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

How can we improve outcomes in Type 2 diabetes?

How can we improve outcomes in Type 2 diabetes? How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace See Important

More information

insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S

insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S insulin degludec/liraglutide 100 units/ml / 3.6mg/mL solution for injection pre-filled pen (Xultophy ) SMC No. (1088/15) Novo Nordisk A/S 4 September 2015 The Scottish Medicines Consortium (SMC) has completed

More information

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma

More information

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes

Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It

More information

New Medicine Assessment

New Medicine Assessment New Medicine Assessment Insulin degludec plus liraglutide (Xultophy ) 100 units/ml insulin degludec plus 3.6 mg/ml liraglutide solution for injection in a pre-filled pen Treatment of adults with type 2

More information

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: LA.PST.14 Effective Date: 03.18 Last Review Date: 3.18 Line of Business: Medicaid Revision Log 1Revision Log 1Revision

More information

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02.

Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: Last Review Date: 02. Clinical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Reference Number: HIM.PA.53 Effective Date: 03.01.18 Last Review Date: 02.19 Line of Business: HIM Revision Log See Important Reminder

More information

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance 580257TAE0010.1177/2042018815580257Therapeutic Advances in Endocrinology and MetabolismSH Tella and MS Rendell research-article2015 Therapeutic Advances in Endocrinology and Metabolism Review Glucagon-like

More information

dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd.

dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. dulaglutide 0.75mg and 1.5mg solution for injection in pre-filled pen (Trulicity ) SMC No. (1110/15) Eli Lilly and Company Ltd. 04 December 2015 The Scottish Medicines Consortium (SMC) has completed its

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 December 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 December 2009 VICTOZA 6 mg/ml solution for injection in pre-filled pen Pack size of two 3 ml pens (CIP: 396 323-6)

More information

New Drug Evaluation: Dulaglutide

New Drug Evaluation: Dulaglutide Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

Update on Insulin-based Agents for T2D

Update on Insulin-based Agents for T2D Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment

More information

Basal Insulin Use With GLP-1 Receptor Agonists

Basal Insulin Use With GLP-1 Receptor Agonists Basal Insulin Use With GLP-1 Receptor Agonists Sarah L. Anderson and Jennifer M. Trujillo University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO Corresponding author:

More information

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several

More information

New Medicine Assessment Semaglutide (Ozempic ) Treatment of Adults with Insufficiently Controlled Type 2 Diabetes

New Medicine Assessment Semaglutide (Ozempic ) Treatment of Adults with Insufficiently Controlled Type 2 Diabetes December 2018 New Medicine Assessment Semaglutide (Ozempic ) Treatment of Adults with Insufficiently Controlled Type 2 Diabetes Recommendation: GREEN Semaglutide is an appropriate treatment option for

More information

MOA: Long acting glucagon-like peptide 1 receptor agonist

MOA: Long acting glucagon-like peptide 1 receptor agonist Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication

More information

Bristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium

Bristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Early treatment for patients with Type 2 Diabetes

Early treatment for patients with Type 2 Diabetes Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona

More information

Presented By: Creative Educational Concepts, Inc. Lexington, KY

Presented By: Creative Educational Concepts, Inc. Lexington, KY Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the

More information

Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists

Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Texas Vendor Drug Program Drug Use Criteria: Glucagon-Like Peptide 1 Receptor Agonists Publication History Developed February 2006. Revised September 2018; September 2016; June 2015; October 2013; December

More information

Glucagon-Like Peptide-1 (GLP-1) Agonists

Glucagon-Like Peptide-1 (GLP-1) Agonists Glucagon-Like Peptide-1 (GLP-1) Agonists Policy Number: 5.01.565 Last Review: 07/2018 Origination: 06/2014 Next Review: 07/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage

More information

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,

More information

ADA Analyst Presentation Saturday 9 th June

ADA Analyst Presentation Saturday 9 th June ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme

More information

Guideline for antihyperglycaemic therapy in adults with type 2 diabetes

Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Guideline for antihyperglycaemic therapy in adults with type 2 diabetes Version Control Version Number Date Amendments made 1 January 2018 1.1 February 2018 Amended to reflect updated SPC advice for sitagliptin

More information

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)

BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) Overarching Shared Care Guideline for Glucagon-like peptide 1 (GLP 1) agonists, February 2017. PATIENT S NAME: PATIENT S ADDRESS: HOSPITAL NAME

More information

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D

Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies. Module D Advances in Outpatient Diabetes Care: Algorithms for Care and the Role of Injectable Therapies Module D 1 Learning Objectives Apply the principles of the comprehensive diabetes algorithms to patients with

More information

Incredible Incretins Abby Frye, PharmD, BCACP

Incredible Incretins Abby Frye, PharmD, BCACP Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike

More information

the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and

the person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness

More information

The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO

The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer

More information

GLP-1 Agonists for Diabetes

GLP-1 Agonists for Diabetes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd

sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

New Drug Evaluation: lixisenatide injection, subcutaneous

New Drug Evaluation: lixisenatide injection, subcutaneous Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes

Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and

More information

Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American

Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American Update on GLP-1 Agonists in Type 2 Diabetes is supported by an educational grant from Novo Nordisk Inc. It has been accredited by the American Association of Diabetes Educators (AADE) for nurses, dietitians,

More information

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name ( Vipidia; Takeda) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Licensed indication To improve glycaemic control in

More information

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY

EFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines

More information

Initiating Injectable Therapy in Type 2 Diabetes

Initiating Injectable Therapy in Type 2 Diabetes Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed

More information

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!

DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and

More information

Basal & GLP-1 Fixed Combination Use

Basal & GLP-1 Fixed Combination Use Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o

More information

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES

INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE

More information

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.

Safety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D. Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is

More information

Francesca Porcellati

Francesca Porcellati XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia

More information

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants

More information

semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic ) Novo Nordisk Ltd.

semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic ) Novo Nordisk Ltd. 1 www.scottishmedicines.org.uk semaglutide 0.25mg, 0.5mg and 1mg solution for injection in pre-filled pen (Ozempic ) Novo Nordisk Ltd. SMC2092 9 November 2018 (Issued 7 December 2018) The Scottish Medicines

More information

dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca

dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 September 2012 (Issued 07 December 2012) The Scottish Medicines Consortium (SMC) has completed

More information

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007

Horizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007 Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited

More information

National Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008

National Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008 Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement

More information

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1

More information

Lilly Diabetes: Pipeline Update

Lilly Diabetes: Pipeline Update Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ

More information

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015 Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages

More information

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:

More information

Dulaglutide (LY ) for the treatment of type 2 diabetes

Dulaglutide (LY ) for the treatment of type 2 diabetes Expert Review of Clinical Pharmacology ISSN: 1751-2433 (Print) 1751-2441 (Online) Journal homepage: http://www.tandfonline.com/loi/ierj20 (LY-2189265) for the treatment of type 2 diabetes André J. Scheen

More information

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare

Disclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011

More information

Dept of Diabetes Main Desk

Dept of Diabetes Main Desk Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is

More information

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes

National Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator

More information

Management of Type 2 Diabetes

Management of Type 2 Diabetes Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity

More information

Initiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital

Initiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most

More information

Faculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI

Faculty. Timothy S. Reid, MD (Co-Chair, Presenter) Medical Director Mercy Diabetes Center Janesville, WI Activity Overview In this case-based webcast, meet Jackie, a 62-year-old woman with type 2 diabetes. Her glycated hemoglobin (HbA1C) is 9.2%, and she is taking 2 oral agents and basal insulin; however,

More information

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse

TREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management

More information

MANAGEMENT OF TYPE 2 DIABETES

MANAGEMENT OF TYPE 2 DIABETES MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol

More information

Injectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017

Injectable Agents for Type 2 Diabetes. Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Injectable Agents for Type 2 Diabetes Richard Christensen, MD AACE Diabetes Day, Boise, ID September 2017 Financial Disclosures Sanofi speaker honoraria No other relevant financial disclosures Injectable

More information

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland.

insulin degludec (Tresiba ) is not recommended for use within NHS Scotland. insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish

More information

GLP-1-based therapies in the management of type 2 diabetes

GLP-1-based therapies in the management of type 2 diabetes GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin

More information

Re-Submission: Published 10 March February 2014

Re-Submission: Published 10 March February 2014 Re-Submission: insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 07 February

More information

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy

3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the

More information

667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY

667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY 667FM.5.1 MANAGEMENT OF TYPE 2 DIABETES: BLOOD-GLUCOSE-LOWERING THERAPY Contents Introduction... 1 Patient Education for People with Type 2 Diabetes... 2 Dietary Advice for People with Type 2 Diabetes...

More information

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens

EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.

More information

The prevalence of type-2 diabetes is increasing at

The prevalence of type-2 diabetes is increasing at Non-insulin injectable therapy The prevalence of type-2 diabetes is rapidly increasing with up to a quarter of people over 60 years of age affected it. To reduce the risk of the associated microvascular

More information

GLP-1RA and insulin: friends or foes?

GLP-1RA and insulin: friends or foes? Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck

More information

1. Comparative effectiveness of liraglutide

1. Comparative effectiveness of liraglutide Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

T max V d t 1/ hours 100 L 3 hours

T max V d t 1/ hours 100 L 3 hours Brand Name: Adlyxin Generic Name: lixisenatide Manufacturer: Sanofi-Aventis U.S. LLC 1 Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist 2,3,4 Uses: Labeled Uses 1,2,3,4,5 : Type 2 diabetes

More information

The Many Faces of T2DM in Long-term Care Facilities

The Many Faces of T2DM in Long-term Care Facilities The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment

More information

Lixisenatide (Adlyxin) A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes

Lixisenatide (Adlyxin) A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes Lixisenatide (Adlyxin) A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes Nicholas Leon, PharmD; Richard LaCoursiere, PharmD; Deirdre Yarosh, MA, PharmD; and Roshni S. Patel, PharmD INTRODUCTION

More information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Timely!Insulinization In!Type!2! Diabetes,!When!and!How Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for

More information

New Drug Evaluation: Insulin degludec, subcutaneous injection

New Drug Evaluation: Insulin degludec, subcutaneous injection Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic

More information

GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.

GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North

More information

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol

Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients

More information

Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy

Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Convenience of Fixed-Ratio Basal Insulin GLP-1 RA Combination Therapy Xavier Cos Catalonian Health Institute Barcelona, Spain Stewart B. Harris Western University London, ON, Canada Basal Insulin GLP-1

More information

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow

Xultophy 100/3.6. (insulin degludec, liraglutide) New Product Slideshow Xultophy 100/3.6 (insulin degludec, liraglutide) New Product Slideshow Introduction Brand name: Xultophy Generic name: Insulin degludec, liraglutide Pharmacological class: Human insulin analog + glucagon-like

More information

UKPDS: Over Time, Need for Exogenous Insulin Increases

UKPDS: Over Time, Need for Exogenous Insulin Increases UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM

More information

Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?

Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health

More information

Liraglutide: First Once-Daily Human GLP-1 Analogue

Liraglutide: First Once-Daily Human GLP-1 Analogue DRUG PROFILE KERALA MEDICAL JOURNAL Liraglutide: First Once-Daily Human GLP-1 Analogue Sreejith N Kumar Research Cell, IMA Kerala State, K-5, Kochar Road, Sasthamangalam Thiruvananthapuram* ABSTRACT Published

More information

empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly

empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly empagliflozin 10mg and 25mg tablet (Jardiance ) SMC No. (993/14) Boehringer Ingelheim / Eli Lilly 05 September 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information